/RAPP
RAPP Stock - Rapport Therapeutics, Inc. Common Stock
Healthcare|BiotechnologyNASDAQ
$30.85+4.08%
+$1.21 (+4.08%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.54
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+47.5%upside
Target: $45.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RAPP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$30.54 – $31.16
TARGET (TP)$45.50
STOP LOSS$28.38
RISK/REWARD1:5.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.65
52W High$42.27
52W Low$6.43
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Gross Profit | $-839,000 | $-112,000 | $-15,000 |
| Gross Margin | N/A | N/A | N/A |
| Operating Income | $-83,055,000 | $-36,179,000 | $-10,367,000 |
| Net Income | $-78,307,000 | $-34,786,000 | $-10,652,000 |
| Net Margin | N/A | N/A | N/A |
| EPS | $-0.38 | $-0.19 | $-0.05 |
Company Overview
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish0 Neutral/Bearish
Price Targets
$38
Average Target
↑ 24.5% Upside
Now
$31
Low
$38
Average
$47
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 19th 2025 | BTIG Research | Initiation | Buy | $47 |
| September 16th 2025 | Truist | Initiation | Buy | $44 |
| August 6th 2025 | H.C. Wainwright | Initiation | Buy | $31 |
| April 8th 2025 | Citizens JMP | Initiation | Mkt Outperform | - |
| July 2nd 2024 | TD Cowen | Initiation | Buy | - |
| July 2nd 2024 | Jefferies | Initiation | Buy | $35 |
| July 2nd 2024 | Stifel | Initiation | Buy | $35 |
Earnings History & Surprises
RAPPBeat Rate
83%
Last 6 quarters
Avg Surprise
-16.1%
EPS vs Estimate
Beats / Misses
5/1
Last 12 quarters
Latest EPS
$-0.71
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q3 24
-150.0%
$-1.70vs$-0.68
Q4 24
+12.3%
$-0.50vs$-0.57
Q1 25
+8.1%
$-0.57vs$-0.62
Q2 25
+11.7%
$-0.68vs$-0.77
Q3 25
+13.8%
$-0.75vs$-0.87
Q4 25
+7.8%
$-0.71vs$-0.77
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 10, 2026 | $-0.65 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.77 | $-0.71 | +7.8% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.87 | $-0.75 | +13.8% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.77 | $-0.68 | +11.7% | ✓ BEAT |
Q1 2025 | Mar 11, 2025 | $-0.62 | $-0.57 | +8.1% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.57 | $-0.50 | +12.3% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.68 | $-1.70 | -150.0% | ✗ MISS |
Q1 2024 | Mar 31, 2024 | — | $-0.12 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.07 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.05 | — | — |
Q2 2023 | Jun 29, 2023 | — | $-0.03 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.03 | — | — |
Latest News
HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $40
📈 PositiveBenzinga•Dec 9, 2025, 06:23 PM
Rapport Therapeutics Announces New Data And Post Hoc Analysis On Clinical And Patient Reported Benefits Of RAP-219 In Drug-Resistant FOS, Alongside Topline Efficacy And Safety Data From Phase 2a FOS Trial
📈 PositiveBenzinga•Dec 5, 2025, 02:03 PM
Rapport Therapeutics Announced That The Company Will Present The Results Of Its Phase 2A Trial Of RAP-219 In Focal Onset Seizures, Along With New Efficacy Analysis, At The Upcoming 2025 American Epilepsy Society Annual Meeting, Taking Place December 5–9, 2025, In Atlanta
📈 PositiveBenzinga•Nov 25, 2025, 12:09 PM
Rapport Therapeutics shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and announced a $47 price target.
📈 PositiveBenzinga•Nov 19, 2025, 06:04 PM•Also:
BTIG Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $47
📈 PositiveBenzinga•Nov 19, 2025, 10:12 AM•Also:
Citizens Maintains Market Outperform on Rapport Therapeutics, Raises Price Target to $80
📈 PositiveBenzinga•Nov 7, 2025, 02:21 PM
Rapport Therapeutics Q3 EPS $(0.71) Beats $(0.77) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:11 PM
Truist Securities Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $44
📈 PositiveBenzinga•Sep 16, 2025, 02:40 PM
Rapport Therapeutics shares are trading lower after the company announced the pricing of a $250 million public offering of 9,615,385 shares at $26 per share.
📉 NegativeBenzinga•Sep 10, 2025, 01:01 PM
Reported Earlier, Rapport Therapeutics Prices $250M Public Offering Of 9,615,385 Shares Of Common Stock At $26 Per Share
➖ NeutralBenzinga•Sep 10, 2025, 07:05 AM
Rapport Therapeutics shares are trading lower after the company announced a $250 million public offering.
📉 NegativeBenzinga•Sep 9, 2025, 03:14 PM
Rapport Therapeutics Launches $250M Public Offering Of Common Stock
➖ NeutralBenzinga•Sep 8, 2025, 08:08 PM
Rapport Therapeutics shares are trading higher after the company announced the Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures met its primary endpoint.
📈 PositiveBenzinga•Sep 8, 2025, 12:42 PM
HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $34
📈 PositiveBenzinga•Sep 8, 2025, 11:43 AM
Market-Moving News for September 8th
➖ NeutralBenzinga•Sep 8, 2025, 11:18 AM•Also: ,
Rapport Therapeutics' Phase 2a Trial Of RAP-219 In Drug-Resistant Focal Onset Seizures Met Its Primary Endpoint, Demonstrating A Statistically Significant Reduction In Long Episodes
📈 PositiveBenzinga•Sep 8, 2025, 10:07 AM
Rapport Therapeutics soars 23% on release of phase 2 data for seizure asset
📈 PositiveSeeking Alpha•Sep 5, 2025, 09:39 PM
Rapport Therapeutics Announces It Will Host A Conference Call And Live Webcast At 8:00 am ET On September 8, 2025, To Report Topline Results For The Phase 2a Trial Of RAP-219 In Patients With Drug-resistant Focal Onset Seizures
➖ NeutralBenzinga•Sep 5, 2025, 08:07 PM
Frequently Asked Questions about RAPP
What is RAPP's current stock price?
Rapport Therapeutics, Inc. Common Stock (RAPP) is currently trading at $30.85 per share. The stock has moved +4.08% today.
What is the analyst price target for RAPP?
The average analyst price target for RAPP is $45.50, based on 1 analyst.
What sector is Rapport Therapeutics, Inc. Common Stock in?
Rapport Therapeutics, Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RAPP's market cap?
Rapport Therapeutics, Inc. Common Stock has a market capitalization of $1.13 billion, making it a small-cap company.
Does RAPP pay dividends?
No, Rapport Therapeutics, Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANAB
AnaptysBio, Inc.
$49.08
Mkt Cap: $1.4B
BBOT
BridgeBio Oncology Therapeutics Inc.
$12.52
Mkt Cap: $1.0B
KOD
Kodiak Sciences Inc.
$26.00
Mkt Cap: $1.4B
MNMD
Mind Medicine (MindMed) Inc.
$12.70
Mkt Cap: $1.0B
NRIX
Nurix Therapeutics, Inc.
$18.52
Mkt Cap: $1.4B
OCS
Oculis Holding AG
$21.25
Mkt Cap: $1.1B
PHAT
Phathom Pharmaceuticals, Inc.
$17.53
Mkt Cap: $1.2B
SEPN
Septerna, Inc.
$29.58
Mkt Cap: $1.3B
URGN
UroGen Pharma Ltd.
$22.80
Mkt Cap: $1.1B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to RAPP for comparison